Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon

被引:21
作者
Frangeul, L
Cresta, P
Perrin, M
Duverlie, G
Khorsi, H
Musset, L
Opolon, P
Huraux, JM
Lunel, F
机构
[1] CHU Pitie Salpetriere, Serv Virol, F-75651 Paris 13, France
[2] CHU Pitie Salpetriere, Serv Hepatogastroenterol, F-75651 Paris, France
[3] CHU Pitie Salpetriere, Serv Immunochim, F-75651 Paris 13, France
[4] CHU Hop Sud, Serv Virol, Amiens, France
[5] Hop Angers, Serv Bacteriol Virol, Angers, France
关键词
anti-HCV antibodies; cryoglobulinemia; hepatitis C virus; interferon; interferon sensitivity determining region (ISDR); NS5A;
D O I
10.1016/S0168-8278(98)80275-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: We aimed to compare the antihepatitis C virus reactivity in confirmatory assays (RIBA 3.0 (C)Ortho Diagnostic and INNO-LIA HCV Ab III (C)Innogenetics) among patients infected with different hepatitis C virus genotypes, with or without cryoglobulinemia, and in patients treated with interferon, Methods: One hundred and three patients followed in our hepatogastroenterology unit were included in the study and compared to 320 consecutive patients tested using RIBA 3.0, Seventy-nine of the 103 patients were treated,vith interferon. Long-term responders to interferon were defined as having normal alanine aminotransferase levels and being HCV RNA negative 6 months after the end of treatment, Initial responders mere defined as having normal alanine aminotransferase levels at the end of interferon therapy but abnormal alanine aminotransferase levels and/or detectable HCV RNA during the following 6 months. Non-responders mere defined as still having elevated alanine aminotransferase during and after interferon, Serological tests (RIBA and INNO-LIA) were performed according to the manufacturers' instructions. HCV RNA was detected by nested polymerase chain reaction. Hepatitis C virus genotype was determined by using a Line Probe Assay ((C)Innogenetics). Results: There was no significant difference in the pattern of hepatitis C virus reactivity according to the hepatitis C virus genotype or presence of cryoglobulinemia. Twenty-three patients were classified as nonresponders, 35 as initial responders, 21 as long-term responders, NS5 reactivity was significantly different (p<0.01) between these three groups: 34% of non-responders (8/23) had RIBA 3.0 NS5 reactivity and 13% (3/23) were reactive in the INNO-LIA III. Almost all long-term responders (95%) had NS5 reactivity by both RIBA 3.0 and INNO-LIA III. Conclusion: We conclude that patients who respond to interferon have stronger reactivity against NS5 antigens than non-responders, Molecular changes in the NS5A region may be responsible for such differences, as recently suggested.
引用
收藏
页码:538 / 543
页数:6
相关论文
共 37 条
  • [31] Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis
    Shaala, Amira Youssef
    Morsi, Mona Gamal
    Harfoush, Reem Abdel Hameed
    ElKhouly, Ehab Hassan
    Ahmed, Mohamed Abdel Rahman
    Roshdy, Mohamed Nabil
    ALEXANDRIA JOURNAL OF MEDICINE, 2015, 51 (03) : 231 - 239
  • [32] Impact of Pre-existing NS5A-L31 or-Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir
    Hernandez, Dennis
    Yu, Fei
    Huang, Xin
    Kirov, Stefan
    Pant, Saumya
    McPhee, Fiona
    ADVANCES IN THERAPY, 2016, 33 (07) : 1169 - 1179
  • [33] Transcriptional Response of MxA, PKR and SOCS3 to Interferon-Based Therapy in HCV Genotype 4-Infected Patients and Contribution of p53 to Host Antiviral Response
    Hamdi, N.
    El-Akel, W.
    El-Serafy, M.
    Esmat, G.
    Sarrazin, C.
    Abdelaziz, A. I.
    INTERVIROLOGY, 2012, 55 (03) : 210 - 218
  • [34] Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir
    Dennis Hernandez
    Fei Yu
    Xin Huang
    Stefan Kirov
    Saumya Pant
    Fiona McPhee
    Advances in Therapy, 2016, 33 : 1169 - 1179
  • [35] Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors
    Kanda, Tatsuo
    Yasui, Shin
    Nakamura, Masato
    Suzuki, Eiichiro
    Arai, Makoto
    Ooka, Yoshihiko
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Saito, Tomoko
    Haga, Yuki
    Takahashi, Koji
    Sasaki, Reina
    Wu, Shuang
    Nakamoto, Shingo
    Tawada, Akinobu
    Maruyama, Hitoshi
    Imazeki, Fumio
    Kato, Naoya
    Yokosuka, Osamu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [36] The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis
    Khairy, Marwa
    Fouad, Rabab
    Mabrouk, Mahassen
    El-Akel, Wafaa
    Awad, Abu Bakr
    Salama, Rabab
    Elnegouly, Mayada
    Shaker, Olfat
    HEPATITIS MONTHLY, 2013, 13 (07)
  • [37] Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection - No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy
    Sugihara, Kanji
    Orito, Etsuro
    Tanaka, Yasuhito
    Kato, Takanobu
    Lau, Johnson Y. N.
    Ohno, Tomoyoshi
    Hayashi, Katsuo
    Ogino, Masataka
    Hirashima, Noboru
    Sakakibara, Kenji
    Mizuno, Yoshiki
    Kato, Hideaki
    Suzuki, Seiji
    Ueda, Ryuzo
    Mizokami, Masashi
    INTERVIROLOGY, 2006, 49 (06) : 319 - 326